Biotech vs COVID-19: The Role of Emerging Technologies in the Fight Against COVID-19 (Part 1)
4 de jun. de 2020 ·
36m 51s
![Biotech vs COVID-19: The Role of Emerging Technologies in the Fight Against COVID-19 (Part 1)](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/3ce94230b297dcbfff5c23f62b0db7e2.jpg)
Descarga y escucha en cualquier lugar
Descarga tus episodios favoritos y disfrútalos, ¡dondequiera que estés! Regístrate o inicia sesión ahora para acceder a la escucha sin conexión.
Descripción
This is part 1 of our event with BioIDEA: Biotech vs COVID-19 BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight...
mostra más
This is part 1 of our event with BioIDEA: Biotech vs COVID-19
BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV.
More from BioIDEA: bioidea.co/
More from A2A Pharmaceuticals: a2apharma.com/
More form OmniCyte: omnicyte.com/
More from EVQLV: evqlv.com/
mostra menos
BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV.
More from BioIDEA: bioidea.co/
More from A2A Pharmaceuticals: a2apharma.com/
More form OmniCyte: omnicyte.com/
More from EVQLV: evqlv.com/
Información
Autor | Daniel Gigante |
Página web | - |
Etiquetas |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company